Author

L. D. Rothermel

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 3 Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 3 Organism:human· 3 Assay:bulk RNA-seq· 2 Research Focus:differential expression· 2 Organism:mouse· 2 Research Focus:cell signaling & trafficking· 1

Frequent Co-Authors

H. J. Graor· 3 shared J. J. Hue· 3 shared J. M. Winter· 3 shared M. Zarei· 3 shared A. Vaziri-Gohar· 2 shared O. Hajihassani· 2 shared A. Abbas· 1 shared E. Prendergast· 1 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 41 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

H. J. Graor

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Targeting wild-type IDH1 enhances chemosensitivity in pancreatic cancer

M. Zarei, O. Hajihassani, J. J. Hue, H. J. Graor, L. D. Rothermel, J. M. Winter

This study shows that targeting wild-type IDH1 enhances chemosensitivity in pancreatic cancer by disrupting redox balance and increasing ROS-induced apoptosis.

bioRxiv · Mar 29, 2023Cancer Biology

Wild-type IDH1 inhibition enhances chemotherapy response in melanoma

M. Zarei, O. Hajihassani, J. J. Hue, H. J. Graor, M. Rathore, A. Vaziri-Gohar, J. M. Asara, J. M. Winter, L. D. Rothermel

This study shows that inhibiting wild-type IDH1 enhances chemotherapy response in melanoma by reducing redox homeostasis and increasing reactive oxygen species.

bioRxiv · May 13, 2022Cancer Biology

Cancer cells are sensitive to wild-type IDH1 inhibition under nutrient limitation

A. Vaziri-Gohar, J. J. Hue, H. J. Graor, E. Prendergast, V. Chen, J. Cassel, F. S. Mohammed, A. Abbas, K. Dukleska, I. Khokhar, O. Hajhassani, M. Zarei, R. Wang, L. D. Rothermel, I. Bederman, , J. M. Winter

This study shows that wild-type IDH1 is a metabolic target in pancreatic cancer cells under nutrient limitation, and FDA-approved drugs can inhibit it effectively in preclinical models.

bioRxiv · Nov 19, 2020 · PreprintCancer Biology